{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihiogylq3qk2rnm2dsto7xq3hsuywxc5eomxkqx4n7mz6sse2cwaa",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mpobp6eqw5x2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreickiz4pfqxsjhsqhysfkuaryvvpoac237x54zk4q5zsox3rocdixm"
    },
    "mimeType": "image/jpeg",
    "size": 247528
  },
  "path": "/news/2026-07-treatment-multiple-sclerosis-shown-effective.html",
  "publishedAt": "2026-07-02T10:20:07.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS). The study, known as OVERLORD-MS, is the first randomized, double-blind, head-to-head trial comparing the two therapies in early MS. Patients from across Norway and Sweden were followed for 30 months with MRI and clinical assessments.",
  "title": "Low-cost treatment for multiple sclerosis shown to be as effective as standard therapy"
}